Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Teva
Express Scripts
Harvard Business School
Cipla
US Department of Justice
UBS
AstraZeneca
Baxter
McKinsey

Generated: October 19, 2017

DrugPatentWatch Database Preview

CHANTIX Drug Profile

« Back to Dashboard

Which patents cover Chantix, and what generic Chantix alternatives are available?

Chantix is a drug marketed by Pfizer Inc and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and eighty-five patent family members in fifty-six countries and eleven supplementary protection certificates in ten countries.

The generic ingredient in CHANTIX is varenicline tartrate. There are eight drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the varenicline tartrate profile page.

Summary for Tradename: CHANTIX

US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list10
Clinical Trials: see list61
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:CHANTIX at DailyMed

Pharmacology for Tradename: CHANTIX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928-001May 10, 2006RXYesNo► Subscribe► SubscribeYY ► Subscribe
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928-001May 10, 2006RXYesNo► Subscribe► Subscribe► Subscribe
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928-001May 10, 2006RXYesNo► Subscribe► Subscribe► Subscribe
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928-002May 10, 2006RXYesYes► Subscribe► SubscribeYY ► Subscribe
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928-002May 10, 2006RXYesYes► Subscribe► Subscribe► Subscribe
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928-001May 10, 2006RXYesNo► Subscribe► SubscribeYY ► Subscribe
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928-001May 10, 2006RXYesNo► Subscribe► SubscribeYY ► Subscribe
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928-001May 10, 2006RXYesNo► Subscribe► Subscribe► Subscribe
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928-002May 10, 2006RXYesYes► Subscribe► SubscribeYY ► Subscribe
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928-002May 10, 2006RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for CHANTIX

Drugname Dosage Strength RLD Submissiondate
varenicline tartrateTablets0.5 mg and 1 mgChantix5/10/2010

Non-Orange Book Patents for Tradename: CHANTIX

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,144,882Aryl fused azapolycyclic compounds► Subscribe
6,605,610 Aryl fused azapolycyclic compounds► Subscribe
6,897,310 Aryl fused azapolycyclic compounds► Subscribe
6,951,938 Aryl fused azapolycyclic compounds► Subscribe
7,205,300Aryl fused azapolycyclic compounds► Subscribe
6,887,884 Aryl fused azapolycyclic compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: CHANTIX

Country Document Number Estimated Expiration
European Patent Office1392307► Subscribe
Czech Republic20032916► Subscribe
Brazil0108610► Subscribe
Malaysia127807► Subscribe
China1406227► Subscribe
Bulgaria65058► Subscribe
Norway326148► Subscribe
Canada2401229► Subscribe
African Regional IP Organization (ARIPO)200202604► Subscribe
Australia2005234671► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CHANTIX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008 00031Denmark► Subscribe
C/GB08/034United Kingdom► SubscribePRODUCT NAME: VARENICLINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE TARTRATE SALT; REGISTRATION NO/DATE: EU/1/06/360/001 - 010 20060928
C021/2008Ireland► SubscribeSPC021/2008: 20081105, EXPIRES: 20210925
0355Netherlands► Subscribe300355, 20181113, EXPIRES: 20220425
442Luxembourg► Subscribe91442, EXPIRES: 20210926
5Finland► Subscribe
2008010,C1044189Lithuania► SubscribePRODUCT NAME: VARENICLINUM TARTRAT; REGISTRATION NO/DATE: EU/1/06/360/001 - EU/1/06/360/010, 0060926
1044189/01Switzerland► SubscribePRODUCT NAME: VARENICLIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57736 21.12.2006
2008000038Germany► SubscribePRODUCT NAME: VARENICLIN GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES UNTER EINSCHLUSS VON TARTRAT; REGISTRATION NO/DATE: EU/1/06/360/001-010 20060926
C0039France► SubscribePRODUCT NAME: VARENICLINE OU L?UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, NOTAMMENT LE TARTRATE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/360/001 DU 20060926; REGISTRATION NO/DATE AT EEC: EU/1/06/360/001 DU 20060926
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Fish and Richardson
Medtronic
Merck
Fuji
Teva
Daiichi Sankyo
Baxter
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot